TCP selected among thousands of applicants to participate
Read TCP’s response filed with the DEA last week here
WASHINGTON, D.C. – The Commonwealth Project (TCP) – an organization working to integrate medical cannabis into mainstream healthcare for seniors – today announced that it was selected by the DEA out of thousands of applicants to participate in the upcoming preliminary hearing on the rescheduling of marijuana. TCP will appear with more than 20 organizations at the hearing set to take place on December 2, with the final rescheduling hearing tentatively scheduled for early Spring 2025.
TCP formally accepted the opportunity to appear at the upcoming hearing through a response to DEA last week – underscoring the potential for medical cannabis to revolutionize senior health care and outlining the risks for seniors if the agency does not act. The full response to the DEA can be found here.
TCP’s efforts are driven by a compassionate desire to assist millions of older adults managing increasingly complex health issues as they age by pioneering a new, innovative and complementary approach to revolutionize the senior healthcare landscape — rooted in the belief that medical cannabis could be harnessed to not only provide older Americans with an alternative to traditional prescription medications, including opioids, but to reduce soaring health care costs saddling millions of seniors.
“The Commonwealth Project understands the potential for medical cannabis to revolutionize health care for the 65+ population by helping patients save money and reduce their consumption of prescription drugs, and we look forward to sharing this perspective and the urgency of this moment with the DEA at the upcoming December hearing,” said Howard Kessler, founder of The Commonwealth Project.
Since its founding in 2019, the Commonwealth Project has offered unparalleled medical expertise regarding the positive impacts of cannabis on senior populations. TCP was the first to study the use of medical cannabis in senior care, inspiring partnerships with medical experts such as Dr. Peter Grinspoon of Massachusetts General Hospital and Harvard Medical School and advocacy giants including LeadingAge, which represents 5,000 aging focused organizations to develop evidence-based programs for the treatment of ailments in the over-65 patient population.
###